Clinical Trial Update: A Study to Examine the Clinical Effectiveness of Tafamidis in Patients With Mixed Phenotype Hereditary Transthyretin Amyloidosis

View source ↗

Summary

Pfizer completed a trial evaluating Tafamidis in mixed-phenotype hereditary transthyretin amyloidosis with cardiomyopathy. Results from the study have been post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiomyopathy
• Hereditary Transthyretin Amyloidosis

Drugs mentioned

• Tafamidis (tafamidis)

Snippet

Sponsor: Pfizer | Conditions: Hereditary Transthyretin Amyloidosis (ATTRv) Cardiomyopathy (CM), Mixed Phenotype | Status: COMPLETED | Results posted: 2024-09-19